Biotech to seek Canadian approval of ALS treatment aiding survival

Biotech to seek Canadian approval of ALS treatment aiding survival

Neurosense Therapeutics announced that it’s preparing a new drug submission to Health Canada — following a meeting with the regulatory agency — to seek approval of PrimeC, its combination therapy for amyotrophic lateral sclerosis (ALS), in the North American nation. During that meeting, the U.S. biotech company presented additional findings from the Phase 2b PARADIGM trial (NCT05357950) — including data showing a median survival benefit of more …